Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
16 hedge funds and large institutions have $152M invested in Ambrx Biopharma Inc in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
12.64% more ownership
Funds ownership: 35.51% → 48.15% (+13%)
7% more funds holding
Funds holding: 15 → 16 (+1)
8% less capital invested
Capital invested by funds: $165M → $152M (-$13.4M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.9M |
| 2 |
AG
Artal Group
Luxembourg
|
+$14.5M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$11.8M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Renaissance Technologies
New York
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$480K |
| 2 |
CCM
CAAS Capital Management
New York
|
-$301K |
| 3 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$203K |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$147K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.4K |
AMAM Hedge Fund Activity: Q4 2021 in Review
16 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q4 2021, worth a combined $152M — down 8.1% from $165M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AMAM positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $22.9M. The largest seller was Millennium Management, cutting an estimated $480K.
- 16 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $152M of Ambrx Biopharma Inc stock for Q4 2021, down 8.1% quarter-over-quarter.
- 2 funds opened new Ambrx Biopharma Inc positions in Q4 2021 and 1 closed out, a net change of +1 holder.
- The largest Ambrx Biopharma Inc buyer in Q4 2021 was BlackRock, an estimated $22.9M added.
- The largest Ambrx Biopharma Inc seller in Q4 2021 was Millennium Management, an estimated $480K sold.
Based on aggregated 13F filings for Q4 2021.